Trials / Completed
CompletedNCT01449370
Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer
A Phase I, Dose Escalation Study of MLN1117 in Subjects With Advanced Solid Malignancies Followed by Expansion in Subjects With Measurable Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 125 (actual)
- Sponsor
- Millennium Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or optimal biologic dose(OBD), safety and tolerability, dose-limiting toxicity (DLT) of TAK-117 when administered orally in subjects with advanced solid malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAK-117 | oral administration of TAK-117, daily and intermittent schedules. |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2015-07-01
- Completion
- 2016-01-01
- First posted
- 2011-10-10
- Last updated
- 2017-03-09
- Results posted
- 2017-03-09
Locations
5 sites across 3 countries: United States, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01449370. Inclusion in this directory is not an endorsement.